Spotlight
Universities should not be greedy with technology spin-offs | FT
Dave Grimm, Partner at AlbionVC, chats to John Gapper, Financial Times, on the opportunities that commercialising research presents, on the back of our very successful partnership with UCL.
UK universities take record low spinout stakes: ‘But that’s only half the battle’
David Grimm, Partner AlbionVC discusses university spinout terms and timelines with Sifted
Ed Lascelles, Partner, speaks with Forbes on the launch of the new Radia 2024 programme
Not Enough Women Are Pitching To VCs: Will An Accelerator Help?
Universities & pharma companies need each other to create world-changing medicines
Simon Goldman highlights the need of closer partnerships between pharma and universitites on Pharmaforum
Bloomsbury GTx announces publication of article highlighting preclinical data from BGT-NPC programme.
A potential new brain-targeted therapeutic for the treatment of Niemann-Pick Type C Disease (NPC).
Quell Therapeutics signs a $2bn plus deal with AstraZeneca | FT
UCLTF cell therapy startup Quell Therapeutics signs a $2bn plus deal with AstraZeneca | FT
Leigh Brody, UCLTF Investor | Career in Discovery Podcast
Leigh Brody, UCLTF investor on TalentSingular’s ‘Careers in discovery’ podcast
Orchard Therapeutics’ new life-saving gene therapy to treat MLD | BBC News
UCLTF’s company has developed a life-saving gene therapy drug now available on the NHS